[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"germ-cell-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:germ-cell-tumor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,49,88,119,141,192,220,247,279,303,328,368,392,418,446,473,497,519,546,566,596,628,656],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100537335","phase-1-phase-1-safety-and-tolerability-study-of-xmab541-in-advanced-solid-tumors-100537335",false,"NCT06276491","Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years\n* CLDN6+ tumor\n* Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment\n* Adequate Eastern Cooperative Oncology Group performance status\n* Life expectancy ≥ 3 months\n* Adequate liver, kidney, and bone marrow function\n\nKey Exclusion Criteria:\n\n* Patients with treated brain metastases may participate, provided they are radiologically stable.\n* Active known or suspected autoimmune disease\n* Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug\n* Clinically significant cardiovascular, pulmonary or gastrointestinal disease\n* Active hepatitis B or hepatitis C","ALL","15 Years",{"count":19,"type":20},282,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.",[26,27,28,29,30],"Ovarian Cancer","Endometrial Cancer","Germ Cell Tumor","Testicular Germ Cell Tumor","Ovarian Germ Cell Tumor",[32,26,33,34,28,27,35],"Phase 1","CLDN6","Testicular Cancer","T-cell Engager","RECRUITING","2026-06-09",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2024-04-04",{"date":44,"type":20},"2028-12",{"name":46,"class":47},"Xencor, Inc.","INDUSTRY",18,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100638426","early-phase-1-feasibility-study-on-the-effect-of-a-methionine-reduced-diet-on-serum-levels-in-pts-w-solid-tumors-100638426","NCT07628634","Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w\u002F Solid Tumors","Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors","Inclusion Criteria:\n\n* Age: Subjects must be 18 years of age or older.\n* Diagnosis: Has a diagnosis of metastatic, recurrent, or unresectable solid tumors.\n* Life Expectancy: Subjects must have an expected life expectancy of at least 3 months.\n* Performance Status: Subjects must have an ECOG performance status of 0-2.\n* Organ Function: Subjects must have adequate organ function, as determined by the investigator through review of standard labs.\n* Pregnancy and Contraception: Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to study enrollment and must agree to use adequate contraception throughout the study period and for 30 days after the last dose of study treatment. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n* Dietary Compliance: Subjects must be willing and able to comply with the methionine-reduced diet as prescribed by the study protocol.\n* Informed Consent: Subjects or Legally Authorized Representatives (LAR) must provide written informed consent prior to any study-specific procedures, indicating that they understand the purpose of the study and are willing to comply with its requirements.\n* Able to receive systemic standard of care cancer therapy.\n\nAdditional criteria specifically for the glioma population:\n\n* Diagnosis: Histopathological proven diagnosis: a) newly diagnosed grade 2-3 glioma or b) all grades for recurrent glioma.\n* Treatment: Subjects must be able to receive radiation therapy and\u002For chemotherapy as a part of their treatment.\n\nExclusion Criteria:\n\n* Brain Metastases: Subjects with uncontrolled or symptomatic brain metastases. Subjects with brain metastases that have been treated, are asymptomatic, and patients who require steroids are eligible.\n* Significant Clinical Illness: Subjects with uncontrolled significant clinical illnesses, including but not limited to: a) Active infections requiring systemic therapy. b) Severe cardiovascular conditions such as recent myocardial infarction (within 6 months), uncontrolled angina, congestive heart failure (NYHA class III or IV), or significant arrhythmias. (c) Uncontrolled diabetes.\n* Significant Amino Acid\u002FMetabolic Illnesses: Subjects with severe or inherited illnesses that affect metabolism of amino acids or disrupt nutrient absorption, including but not limited to: a) Severe liver disease, such as cirrhosis or severe hepatic insufficiency, that may have compromised ability to metabolize amino acids. b) Inherited metabolic disorders, such as homocystinuria or other disorders affecting sulfur amino acid metabolism, that may have potential metabolic imbalances. c) Severe gastrointestinal disorders, such as active inflammatory bowel disease (IBD), short bowel syndrome, or other conditions that significantly impair nutrient absorption, that may lead to nutritional deficiencies and gastrointestinal complications.\n* Recent Surgery: Major surgery within 4 weeks of randomization (biopsies are acceptable per investigator judgement)\n* Concurrent Malignancies: Subjects with another malignancy that requires active treatment during the study period or is expected to interfere with the study intervention.\n* Pregnancy or Lactation: Female subjects who are pregnant or breastfeeding.\n* Malnutrition: Subjects with severe malnutrition or significant nutritional deficiencies per investigator's discretion.\n* Substance Abuse: Subjects with a history of substance abuse or dependency within the past 6 months that, in the opinion of the investigator, would interfere with adherence to study requirements.\n* Subjects with chronic kidney disease with advanced stages 3b or higher.\n* Psychiatric Disorders: Subjects with psychiatric disorders that would interfere with the ability to give informed consent or adhere to study requirements per investigator judgment.\n* Subjects with known allergies or intolerances to low-methionine foods.\n* Subjects with any medical or surgical conditions that, in the opinion of the investigator, would make adherence to the methionine-reduced diet unsafe or impractical.","18 Years",{"count":58,"type":20},25,[60],"EARLY_PHASE1","This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.",[63,64,65,66,67,68,69,70,71,72,73,28,74,75,76],"Adenocarcinoma","Basal Cell Carcinoma","Squamous Cell Carcinoma","Transitional Cell Carcinoma","Ductal Carcinoma","Osteosarcoma","Soft Tissue Sarcoma","Ewing Sarcoma","Rhabdomyosarcoma","Leiomyosarcoma","Melanoma","Lymphoma","Endocrine Tumor","Glioma","2026-06-02",{"date":79,"type":40},"2026-06-05",{"date":81,"type":40},"2026-05-01",{"date":83,"type":20},"2028-05-01",{"name":85,"class":86},"University of California, Irvine","OTHER",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":58},"100605576","phase-1-a-study-of-zw251-in-participants-with-advanced-solid-tumors-100605576","NCT07164313","A Study of ZW251 in Participants With Advanced Solid Tumors","A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and\u002For metastatic disease. Noninvasive methods may be used to confirm diagnosis\n* Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and\u002For metastatic disease\n* Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and\u002For choriocarcinoma predominant component and locally advanced (unresectable) and\u002For metastatic disease\n* Measurable disease per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Liver function status of Child-Pugh Class A (for HCC only)\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known additional malignancy that is progressing or that has required active treatment within the last year\n* History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy\n* Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment\n* Known gastrointestinal bleeding within 3 months\n* Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease",{"count":96,"type":20},100,[23],"The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).",[100,101,28],"Hepatocellular Carcinoma","Squamous Cell Non-Small Cell Lung Cancer",[103,104,105,106,107,108,109,28],"GPC3-expressing cancer","hepatocellular carcinoma","antibody drug conjugate","ADC","Lung Cancer","Non-Small Cell Lung Cancer","Squamous Cell Cancer","2026-05-05",{"date":112,"type":40},"2026-05-07",{"date":114,"type":40},"2025-10-21",{"date":116,"type":20},"2028-05",{"name":118,"class":47},"Zymeworks BC Inc.",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":139,"locationsCount":87},"100424216","phase-2-maintenance-oral-etoposide-or-observation-following-high-dose-chemo-for-gct-100424216","NCT04804007","Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT","Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information\n2. Age ≥ 18 years at the time of consent\n3. Histological or serological evidence of non-seminomatous GCT\n4. Relapsed disease after first-line cisplatin-based combination chemotherapy\n5. Completed salvage treatment with HDCT and PBSCT for 2 tandem cycles per Institutional Guidelines\n6. HDCT must have been used as the initial salvage chemotherapy regimen (2nd line therapy) 6.1. Note: 1 or 2 cycles of standard course regimens prior to HDCT are acceptable (regimens include VeIP \\[vinblastine+ifosfmaide+cisplatin\\] or TIP \\[paclitaxel+ifosfamide+cisplatin\\] or PVB \\[cisplatin+vinblastine+bleomycin\\]\n7. Normal or declining tumor markers (AFP and hCG) at time of screening\n8. Adverse events from prior therapy recovered to CTCAE v5.0 grade ≤ 2 at time of registration\n9. Women with ovarian germ cell tumors are eligible\n10. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 28 days of study registration\n11. Last dose of HDCT must be ≤16 weeks from study registration\n12. Adequate organ function lab values obtained within 28 days prior to study registration System Laboratory Value Hematological Absolute neutrophil count (ANC) ≥1,000 \u002FmcL Platelets ≥100,000 \u002F mcL Hemoglobin ≥8 g\u002FdL Renal Serum creatinine \\\u003C2mg\u002FdL Hepatic Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN\n\n    AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR\n    * 5 X ULN for subjects with liver metastases Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n13. If a female of childbearing potential, a negative urine pregnancy test within 28 days prior to receiving the first dose of study drug.\n\n    o Non-childbearing potential is defined as (by other than medical reasons):\n    * ≥ 45 years of age and has not had menses for \\>2 years\n    * Amenorrheic for \\\u003C 2 years without a hysterectomy and\u002For oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation\n    * Post hysterectomy or oophorectomy. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound.\n14. For female patients of childbearing potential and male patients, agreement (by patient and\u002For partner) to use two forms of highly effective contraception (i.e., one that results in a low failure rate \\[\\\u003C 1% per year\\] when used consistently and correctly) starting with the first dose of study therapy and to continue its use for 30 days after the last dose of study therapy, or abstain from heterosexual activity.\n\nExclusion Criteria:\n\n1. Relapsed pure seminoma\n2. Rising tumor markers (AFP and hCG) at time of screening\n3. Patients who completed 2nd cycle of HDCT (time since last dose of HDCT) \\>16 weeks ago\n4. Treatment with any investigational agent within 28 days prior to study registration\n5. Other active malignancy requiring treatment in past 12 months\n6. History of psychiatric illness or social situations that would limit compliance with study requirements\n7. Active infection requiring systemic therapy\n8. Previous hypersensitivity to etoposide which did not recover with supportive care\n9. Pregnancy, lactation, or breastfeeding\n10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",{"count":127,"type":20},64,[129],"PHASE2","This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).",[28,132,30],"Non-seminomatous Germ Cell Tumor",[28],{"date":135,"type":40},"2026-05-08",{"date":137,"type":40},"2021-03-03",{"date":44,"type":20},{"name":140,"class":86},"Nabil Adra",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":191},"100290931","phase-3-active-surveillance-bleomycin-etoposide-carboplatin-or-cisplatin-in-treating-pediatric-and-adult-patients-with-germ-cell-tumors-100290931","NCT03067181","Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors","A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors","Inclusion Criteria:\n\n* There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT \\[all sites\\])\n* Standard risk 1: Patients must be \\\u003C 11 years of age at enrollment\n* Standard risk 2: Patients must be \\>= 11 and \\\u003C 25 years of age at enrollment\n* Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with malignant germ cell tumor (stage II or higher).\n\n  * Histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment , with the following exceptions:\n\n    * Among patients were initially diagnosed with completely resected non-seminoma malignant GCT and later recur during observation post surgery, a diagnostic biopsy is not required for enrollment if elevated tumor markers rise to \\> 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart. The pathology report of initial surgery should be provided\n    * Patients may be enrolled without histologic or cytologic confirmation in the rare case where there are exceptionally raised tumor markers (alpha fetoprotein \\[AFP- ≥ 500 ng\u002FmL or HCG ≥ 500 IU\u002FL) and radiologic features consistent with GCT. In addition, the treating clinician must deem that the patient's tumor is not suitable for upfront resection and that a biopsy is not in the patient's best interest; or that there is a need to start therapy urgently\n* Low risk immature teratoma (IT); site: ovarian; stage: any; grade: any; histology: pure immature teratoma, mixed immature and mature teratoma, (may contain microscopic foci of yolk sac tumor \\[\\\u003C 3 mm\\], but no other pathological evidence of MGCT); tumor markers: alpha-FP =\\\u003C 1,000 ng\u002FmL, beta-HCG institutional normal; all ages\n* Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages\n* Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: must contain only seminoma; may contain immature\u002Fmature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages\n* Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC-IV, (International Germ Cell Consensus Classification \\[IGCCC\\] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) \\\u003C 11\n* Standard risk 2 (SR2)\n\n  * Site: ovarian; stage: COG stage II, III, and III-X, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) \\>= 11 and \\\u003C 25\n  * Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma: must be IGCCC good risk; post op: alpha-FP \\\u003C 1,000 ng\u002FmL, beta-HCG \\\u003C 5,000 IU\u002FmL and lactate dehydrogenase (LDH) \\\u003C 3.0 x normal; age (years) \\>= 11 and \\\u003C 25\n* Notes:\n\n  * IGCCC criteria only apply to SR2 patients with a testicular primary tumor\n  * Use post-op tumor marker levels to determine IGCCC risk group\n  * Pure seminoma patients are not eligible for the standard risk arms of the study\n  * For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a \"microscopic component\" of yolk sac tumor\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients \\> 16 years of age and Lansky for patients =\\\u003C 16 years of age\n* Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients)\n* Adequate renal function defined as:\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 mL\u002Fmin\u002F1.73 m\\^2 (within 7 days prior to enrollment) OR\n* A serum creatinine based on age\u002Fsex as follows (within 7 days prior to enrollment): (mg\u002FdL)\n\n  * 1 month to \\\u003C 6 months male: 0.4 female: 0.4\n  * 6 months to \\\u003C 1 year male: 0.5 female: 0.5\n  * 1 to \\\u003C 2 years male: 0.6 female: 0.6\n  * 2 to \\\u003C 6 years male: 0.8 female: 0.8\n  * 6 to \\\u003C 10 years male: 1 female: 1\n  * 10 to \\\u003C 13 years male: 1.2 female: 1.2\n  * 13 to \\\u003C 16 years: male: 1.5 female: 1.4\n  * \\>= 16 years male: 1.7 female: 1.4\n* Total bilirubin =\\\u003C 2 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)\n\n  * Unless due to Gilbert's disease, malignant involvement of liver or vanishing bile duct syndrome\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 x upper limit of normal (ULN) (within 7 days prior to enrollment)\n\n  * Unless due to Gilbert's disease, malignant involvement of liver or vanishing bile duct syndrome\n* Peripheral absolute neutrophil count (ANC) \\>= 750\u002Fmm\\^3 (within 7 days prior to enrollment) AND\n* Platelet count \\>= 75,000\u002Fmm\\^3 (within 7 days prior to enrollment)\n* Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment\n* Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes \\[PROs\\] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate\n* \\>= 11 and \\\u003C 25 years old at enrollment\n* Able to fluently speak and read English\n* Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor\n* Followed for cancer or survivorship care at one of the following institutions:\n\n  * Baylor College of Medicine\u002FDan L Duncan Comprehensive Cancer Center\n  * Dana Farber\u002FHarvard Cancer Center\n  * Hospital for Sick Children\n  * Children's Hospital of Eastern Ontario\n  * Oregon Health and Science University\n  * Seattle Children's Hospital\n  * Yale University\n\nExclusion Criteria:\n\n* Patients with any diagnoses not listed including:\n\n  * Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection)\n  * Pure ovarian or extragonadal dysgerminoma\u002Fseminoma\n  * Pure mature teratoma\n  * Pure immature teratoma with alpha-fetoprotein (AFP) \\>= 1000 ng\u002FmL\n  * \"Poor risk\" GCT (age \\>= 11 years old and COG stage IV ovarian, COG stage II- IV extragonadal, or IGCCC intermediate or poor risk testicular), or\n  * Primary central nervous system (CNS) germ cell tumor\n  * Germ cell tumor with somatic malignant transformation\n  * Spermatocytic seminoma\n* Patients must have had no prior systemic therapy for the current cancer diagnosis\n* Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain \\[stage IV disease\\] would be considered poor risk and therefore not eligible for this trial)\n* Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial\n* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy \\[SR1 and SR2 patients\\])\n* Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy \\[SR1 and SR2 patients\\])\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy \\[SR1 and SR2 patients\\])",{"count":149,"type":20},1780,[151],"PHASE3","This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.",[154,155,28,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182],"Childhood Extracranial Germ Cell Tumor","Extragonadal Embryonal Carcinoma","Malignant Germ Cell Tumor","Malignant Ovarian Teratoma","Stage I Ovarian Choriocarcinoma","Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage I Testicular Choriocarcinoma AJCC v6 and v7","Stage I Testicular Embryonal Carcinoma AJCC v6 and v7","Stage I Testicular Seminoma AJCC v6 and v7","Stage I Testicular Yolk Sac Tumor AJCC v6 and v7","Stage II Ovarian Choriocarcinoma","Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage II Testicular Choriocarcinoma AJCC v6 and v7","Stage II Testicular Embryonal Carcinoma AJCC v6 and v7","Stage II Testicular Yolk Sac Tumor AJCC v6 and v7","Stage III Ovarian Choriocarcinoma","Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7","Stage III Testicular Choriocarcinoma AJCC v6 and v7","Stage III Testicular Embryonal Carcinoma AJCC v6 and v7","Stage III Testicular Yolk Sac Tumor AJCC v6 and v7","Stage IV Ovarian Choriocarcinoma","Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7","Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7","Testicular Mixed Choriocarcinoma and Embryonal Carcinoma","Testicular Mixed Choriocarcinoma and Teratoma","Testicular Mixed Choriocarcinoma and Yolk Sac Tumor",{"date":110,"type":40},{"date":185,"type":40},"2017-05-25",{"date":187,"type":20},"2027-06-30",{"name":189,"class":190},"Children's Oncology Group","NETWORK",629,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":205,"conditions":206,"keywords":209,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":87},"100597165","tumor-lymph-node-mapping-100597165","NCT07054944","Tumor-Lymph Node Mapping","FEASIBILITY AND SAFETY OF INDOCYANINE GREEN (ICG) GUIDED SENTINEL LYMPH NODE MAPPING FOR PEDIATRIC SOLID TUMORS - T-LyM (Tumor-Lymph Node Mapping)","T-LyM","Inclusion Criteria:\n\n* Any pediatric patient (under the age of 18 years) being treated at the University of Rochester Medical Center, Department of Surgery.\n* Diagnosed with pediatric solid tumor\n* Scheduled to undergo lymph node sampling as part of their clinical management.\n\nExclusion Criteria:\n\n* Subjects with a history of iodide allergies.\n* Inability or unwillingness of research participant or parent\u002Flegal guardian to give written informed consent.\n* Currently pregnant.\n* Infants under 650 grams.\n* Patients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainage.","1 Month","17 Years",{"count":203,"type":20},10,"OBSERVATIONAL","The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection\u002Fsampling.\n\nThis trial is a single-site cross-sectional study. The injection of ICG directly into lymphatics draining the primary tumor will take place at the time of operation after the patient is under anesthesia.",[207,71,208,28],"Pediatric Solid Tumors","Sarcoma",[210],"PEDIATRIC CANCER","2026-04-20",{"date":213,"type":40},"2026-04-23",{"date":215,"type":20},"2026-04-13",{"date":217,"type":20},"2028-07-30",{"name":219,"class":86},"University of Rochester",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":87},"100386177","phase-1-vorinostat-in-combination-with-chemotherapy-in-relapsedrefractory-solid-tumors-and-cns-malignancies-100386177","NCT04308330","Vorinostat in Combination With Chemotherapy in Relapsed\u002FRefractory Solid Tumors and CNS Malignancies","A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies","NYMC195","Inclusion Criteria:\n\n* Age: Patients must be less than or equal to 1 year and less than or equal to 30 years of age at initiation of protocol therapy.\n* Diagnosis: Patients must have a confirmed histologic diagnosis of a relapsed or refractory solid tumor or CNS malignancy.\n* Performance status: Patients over 16 years of age must have a Karnofsky score greater than or equal to 50. Children under 16 years of age must have a Lansky score greater than or equal to 50.\n* Prior therapy: Patients may have received prior therapy with vincristine, irinotecan, or temozolomide. They may not however have received therapy that included a treatment cassette of irinotecan and temozolomide in combination.\n\n  * Prior myelosuppressive therapy: Patients must have not received myelosuppressive therapy in 3 weeks or nitrosourea chemotherapy within 6 weeks of initiation of protocol therapy.\n  * Hematologic growth factor support: Patients may not have received G-CSF within the previous 3 days or peg-filgrastim within the past 7 days.\n  * Biologic anti-neoplastic therapy: At least 21 days or 5 half-lives (whichever is of longer duration) must have elapsed since the last administration of biologic antineoplastic therapy.\n  * Radiation therapy: ≥ 14 days since the last dose of local XRT; ≥ 6 months must have elapsed if prior TBI, craniospinal XRT or ≥ 50% radiation of pelvis; ≥ 6 wks must have elapsed if other substantial BM radiation.\n  * Autologous or allogeneic stem cell transplant: No active graft vs. host disease or need for immunosuppressive therapy. At least 3 months must have passed since neutrophil engraftment.\n* Organ function:\n\nBone marrow function:\n\n* Peripheral absolute neutrophil count (ANC) greater than or equal to 1000 cells\u002FmcL.\n* Platelet count greater than or equal to100,000\u002FmcL and no platelet transfusion within prior 7 days.\n* Hemoglobin greater than or equal to 8 gm\u002FdL\n* Patients with known bone marrow metastatic disease may enroll on the study if they have a peripheral ANC greater than or equal to 750 cells\u002FmcL. They will not be evaluable for hematologic toxicity.\n\n  \\- Adequate liver function:\n* Total bilirubin less than or equal to 1.5x upper limit of normal (ULN) for age.\n* SGPT (ALT) less than or equal to 5x ULN\n* Serum albumin greater than or equal to 2 gm\u002FdL\n\n  \\- Adequate renal function:\n* Creatinine clearance or glomerular filtration rate \\>70 ml\u002Fmin\u002F1.73 m2 or a serum creatinine based on age and gender as follows:\n\nAge Maximum serum creatinine concentration (mg\u002FdL) Male Female 1-\\\u003C2 years 0.6 0.6 2-\\\u003C6 years 0.8 0.8 6-\\\u003C10 years 1 1 10-\\\u003C13 years 1.2 1.2 13-\\\u003C16 years 1.5 1.4 greater than or equal to 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula to estimate glomerular filtration rates (Schwartz et al. J. Peds. 106; 522. 1985) using child length and stature data from the CDC.\n\n\\- Informed consent: All patients less than 18 years of age must sign a written informed consent. For patients \\\u003C18 years of age, a parent or guardian must sign a written informed consent, unless the patient is an emancipated minor. Childhood assent, when appropriate, should be obtained as well per institutional guidelines.\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding: Women who are pregnant or breast feeding will not be entered on the protocol due to the risks of fetal and teratogenic adverse events with the therapeutic agents used in the protocol therapy.\n* Corticosteroid use: Patients with CNS tumors who have not been on a stable or decreasing dose of corticosteroids for the 7 days prior to the initiation of protocol therapy.\n* Antineoplastic therapy: Patients receiving any other antineoplastic therapy.\n* Medication allergy:\n\nAllergy or intolerance to any of the protocol agents: vincristine, irinotecan, temozolomide, or vorinostat.\n\nAllergy or intolerance to cephalosporins.\n\n* Infection: Patients who have any uncontrolled infection, positive blood culture within 48 hours prior to protocol entry, or diagnosed or receiving therapy for Clostridium difficile infection.\n* Patients may not have taken valproic acid or any other histone deacetylase inhibitor for at least 2 weeks prior to study enrollment.\n* Children with neurofibromastosis Type 1, if being used for treatment of a low grade glioma.","1 Year","30 Years",{"count":231,"type":20},30,[23],"Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy.\n\nThe goals of this study are:\n\n* To find the highest safe dose of vorinostat that can be given together with vincristine, irinotecan, and temozolomide without causing severe side effects;\n* To learn what kind of side effects this four drug combination can cause;\n* To learn about the effects of vorinostat and the combination of vorinostat, vincristine, irinotecan, and temozolomide on specific molecules in tumor cells;\n* To determine whether the combination of vorinosat, vincristine, irinotecan, and temozolomide is a beneficial treatment.",[70,71,235,236,237,28],"Wilms Tumor","Neuroblastoma","Hepatoblastoma","2026-04-10",{"date":240,"type":40},"2026-04-15",{"date":242,"type":40},"2017-03-17",{"date":244,"type":20},"2027-12-31",{"name":246,"class":86},"New York Medical College",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":269,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":87},"100376708","phase-1-study-of-b7-h3-specific-car-t-cell-locoregional-immunotherapy-for-diffuse-intrinsic-pontine-gliomadiffuse-midline-glioma-and-recurrent-or-refractory-pediatric-central-nervous-system-tumors-100376708","NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors","Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors","Inclusion Criteria:\n\n1. Age ≥ 1 and ≤ 26 years\n2. Diagnosis of refractory or recurrent CNS disease for which there is no standard therapy, or diagnosis of DIPG or DMG at any time point following completion of standard therapy\n3. Able to tolerate apheresis, or has apheresis product available for use in manufacturing\n4. CNS reservoir catheter, such as an Ommaya or Rickham catheter\n5. Life expectancy ≥ 8 weeks\n6. Lansky or Karnofsky score ≥ 60\n7. If patient does not have previously obtained apheresis product, patient must have discontinued, and recovered from acute toxic effects of, all prior chemotherapy, immunotherapy, and radiotherapy and discontinue the following prior to enrollment:\n\n   1. ≥ 7 days post last chemotherapy\u002Fbiologic therapy administration\n   2. 3 half lives or 30 days, whichever is shorter post last dose of anti-tumor antibody therapy\n   3. Must be at least 30 days from most recent cellular infusion\n   4. All systemically administered corticosteroid treatment therapy must be stable or decreasing within 1 week prior to enrollment with maximum dexamethasone dose of 2.5 mg\u002Fm2\u002Fday. Corticosteroid physiologic replacement therapy is allowed.\n8. Adequate organ function\n9. Adequate laboratory values\n10. Patients of childbearing\u002Ffathering potential must agree to use highly effective contraception\n\nExclusion Criteria:\n\n1. Presence of Grade ≥ 3 cardiac dysfunction or symptomatic arrhythmia requiring intervention\n2. Presence of primary immunodeficiency\u002Fbone marrow failure syndrome\n3. Presence of clinical and\u002For radiographic evidence of impending herniation\n4. Presence of \\>Grade 3 dysphagia\n5. Presence of active malignancy other than the primary CNS tumor under study\n6. Presence of active severe infection\n7. Receiving any anti-cancer agents or chemotherapy\n8. Pregnant or breastfeeding\n9. Subject and\u002For authorized legal representative unwilling or unable to provide consent\u002Fassent for participation in the 15 year follow up period\n10. Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol","26 Years",{"count":256,"type":20},90,[23],"This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are delivered via an indwelling catheter into the tumor resection cavity or ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and recurrent or refractory CNS tumors.\n\nA child or young adult meeting all eligibility criteria, including having a CNS catheter placed into the tumor resection cavity or into their ventricular system, and meeting none of the exclusion criteria, will have their T cells collected. The T cells will then be bioengineered into a second-generation CAR T cell that targets B7H3-expressing tumor cells. Patients will be assigned to one of 3 treatment arms based on location or type of their tumor. Patients with supratentorial tumors will be assigned to Arm A, and will receive their treatment into the tumor cavity. Patients with either infratentorial or metastatic\u002Fleptomeningeal tumors will be assigned to Arm B, and will have their treatment delivered into the ventricular system. The first 3 patients enrolled onto the study must be at least 15 years of age and assigned to Arm A or Arm B. Patients with DIPG will be assigned to Arm C and have their treatment delivered into the ventricular system. The patient's newly engineered T cells will be administered via the indwelling catheter for two courses. In the first course patients in Arms A and B will receive a weekly dose of CAR T cells for three weeks, followed by a week off, an examination period, and then another course of weekly doses for three weeks. Patients in Arm C will receive a dose of CAR T cells every other week for 3 weeks, followed by a week off, an examination period, and then dosing every other week for 3 weeks. Following the two courses, patients in all Arms will undergo a series of studies including MRI to evaluate the effect of the CAR T cells and may have the opportunity to continue receiving additional courses of CAR T cells if the patient has not had adverse effects and if more of their T cells are available.\n\nThe hypothesis is that an adequate amount of B7H3-specific CAR T cells can be manufactured to complete two courses of treatment with 3 or 2 doses given on a weekly schedule followed by one week off in each course. The other hypothesis is that B7H3-specific CAR T cells can safely be administered through an indwelling CNS catheter or delivered directly into the brain via indwelling catheter to allow the T cells to directly interact with the tumor cells for each patient enrolled on the study. Secondary aims of the study will include evaluating CAR T cell distribution with the cerebrospinal fluid (CSF), the extent to which CAR T cells egress or traffic into the peripheral circulation or blood stream, and, if tissues samples from multiple timepoints are available, also evaluate disease response to B7-H3 CAR T cell locoregional therapy.",[260,261,262,263,264,28,265,266,267,268,76],"Central Nervous System Tumor","Diffuse Intrinsic Pontine Glioma","Diffuse Midline Glioma","Ependymoma","Medulloblastoma, Childhood","Atypical Teratoid\u002FRhabdoid Tumor","Primitive Neuroectodermal Tumor","Choroid Plexus Carcinoma","Pineoblastoma, Childhood",[270],"CNS, CAR T cell, B7-H3, pediatric, young adult, brain tumor, DIPG, DMG","2026-04-07",{"date":215,"type":40},{"date":274,"type":40},"2019-12-11",{"date":276,"type":20},"2042-05",{"name":278,"class":86},"Seattle Children's Hospital",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":285,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":302},"100216816","germ-cell-tumor-and-testicular-tumor-dna-registry-100216816","NCT02099734","Germ Cell Tumor and Testicular Tumor DNA Registry","Inclusion Criteria:\n\nCase Cohort\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must have a diagnosis or suspicion of germ cell tumor and\u002For a testicular mass\n\nFamily Member Cohort\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.\n\nControl Cohort\n\n* Must be ≥ 18 years of age AND\n* Must be an English-speaker AND\n* Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND\n* Must not have a family history of germ cell tumor or testicular tumor AND\n* Must not be a blood relative of controls enrolled in this study\n\nExclusion Criteria:",true,{"count":287,"type":20},1000,"This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.",[28,290],"Testicular Tumor",[292],"14-016","2026-02-02",{"date":295,"type":40},"2026-02-04",{"date":297,"type":40},"2014-01",{"date":299,"type":20},"2028-01",{"name":301,"class":86},"Memorial Sloan Kettering Cancer Center",8,{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100582719","phase-2-a-single-arm-phase-ii-clinical-trial-of-aspirin-to-prevent-venous-thromboembolism-in-patients-with-advanced-germ-cell-tumors-receiving-chemotherapy-100582719","NCT06866964","A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy","ASPIRE","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information\n2. Age ≥ 18 years and ≤ 70 years at the time of consent\n3. Histological confirmation of stage IS or IIA or higher testicular or germ cell cancer. Primary mediastinal and retroperitoneal GCT are allowed. Seminoma and non-seminoma histologies are allowed.\n4. Performance Status (PS) of ECOG 0-2 at the time of enrollment\n5. At least one of the following \"high risk\" of VTE features:\n\n   a. Stage IIC or III or higher per AJCC 8th edition criteria i. Stage IIC - any pT\u002FTX, N3, M0, S0-1 ii. Stage III - any pT\u002FTX, any N, M1, SX iii. Stage IIIA - any pT\u002FTX, any N, M1a, S0-1 iv. Stage IIIB - any pT\u002FTX, N1-3, M0, S2 or any pT\u002FTX, any N, M1a, S2 v. Stage IIIC - any pT\u002FTX, N1-3, M0, S3 or any pT\u002FTX, any N, M1a, S3 or any pT\u002FTX, any N, M1b, any S Serum marker (S category) S criteria SX Marker studies not available or not performed S0 Marker study levels within normal limits S1 LDH \\\u003C 1.5 x normal and hCG \\\u003C 5000 IU\u002FL and AFP \\\u003C1000 ng\u002FmL S2 LDH 1.5 to 10 x normal or hCG 5000 to 50,000 IU\u002FL or AFP 1000 to 10,000 ng\u002FmL S3 LDH \\>10 x normal or hCG \\>50,000 IU\u002FL or AFP \\>10,000 ng\u002FmL\n\n   b. Intermediate or poor risk by IGCCCG criteria i. Intermediate risk - testis\u002Fretroperitoneal primary and no non pulmonary visceral metastases plus at least one of the following markers: AFP \\> 1,000 ng\u002FmL to ≤ 10,000 ng\u002FmL, beta-hCG \\> 5,000 IU\u002FL and ≤ 50,000 IU\u002FL, LDH \\>1.5 x normal and ≤ 10 x normal ii. Poor risk - mediastinal primary or non-pulmonary visceral metastases plus at least one of the following markers: AFP \\> 10,000 ng\u002FmL, beta- hCG \\> 50,000 IU\u002FL, LDH \\> 10 x normal c. Khorana score of 2 or higher i. +1 point for testicular\u002Fgerm cell cancer (All patients will receive +1 for their testicular\u002Fgerm cell cancer diagnosis. Thus, a patient with any other Khorana characteristic \\[ii-v\\] will meet this inclusion criteria.) ii. +1 point for platelet ≥350 x 10\\^9\u002FL iii. +1 point for hemoglobin \\\u003C10 g\u002FdL iv. +1 point for leukocyte count \\>11 x 10\\^9\u002FL v. +1 point for BMI \\>35 kg\u002Fm\\^2\n6. Planning or recently started 3-4 cycles of standard of care front-line cisplatin-based chemotherapy (bleomycin, etoposide, and platinum \\[BEP\\], etoposide and cisplatin \\[EP\\], or etoposide, ifosfamide, and cisplatin \\[VIP\\]). Note: ASA should be initiated no later than 2 weeks after initiation of standard front-line chemotherapy.\n7. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n8. Ability to swallow oral medications\n\nExclusion Criteria:\n\n1. Receiving chemotherapy in adjuvant setting\n2. Prior VTE\u002FPE\n3. Currently taking anticoagulation or antiplatelet therapy. Non-steroidal anti-inflammatory drug (NSAID) use for pain is allowed\n4. Prior indication for anticoagulation or anticoagulation contraindicated (e.g., active bleed or risk of bleeding, such as history of gastrointestinal ulcers)\n5. Allergy to ASA","70 Years",{"count":312,"type":20},35,[129],"The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls",[28,34],[317,318],"cancer","Venous thromboembolism","2026-01-30",{"date":293,"type":40},{"date":322,"type":40},"2025-08-28",{"date":324,"type":20},"2031-01",{"name":326,"class":86},"Wake Forest University Health Sciences",3,{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":335,"targetDuration":337,"studyType":204,"phases":4,"briefSummary":338,"conditions":339,"keywords":350,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":367},"100459206","observational-study-for-assessing-treatment-and-outcome-of-patients-with-primary-brain-tumours-using-cimpact-now-and-2021-who-classification-100459206","NCT05259605","Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification","Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Diagnosed According to cIMPACT-NOW Recommendations and the 2021 WHO Classification","* Age ≥ legal age of consent\n* Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest\n* Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16.\n* Available MRI\u002FCT scans from primary brain tumour at initial diagnosis\n* Patient's consent\n\nDeceased patient:\n\nThe clinical data and\u002For biological material and\u002For CT\u002FMRI\u002FPET images can be accessed and used if at least one of the following three conditions is met:\n\n* The patient agreed beforehand in his\u002Fher lifetime to a further use of his\u002Fher data and\u002For biological material and\u002For CT\u002FMRI\u002FPET images, or,\n* There is consent of a relative to use data and\u002For biological material and\u002For CT\u002FMRI\u002FPET images of the deceased patient, or,\n* There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients).\n\nAdditionally, in all cases the following three points need to be fulfilled:\n\n* No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT\u002FMR\u002FPET images for research purposes\n* A notification to an ethics committee for the re-use of these data, biological material and CT\u002FMRI\u002FPET images\n* Any other national requirements are fulfilled, if applicable",{"count":336,"type":20},1650,"10 Years","Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.\n\nThe goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.",[76,340,341,342,28,343,344,263,345,346,347,348,349],"Glioneuronal Tumor","Choroid Plexus Tumor","Pineal Tumors","Tumor of the Sellar Region","Diffuse Midline Glioma, H3 K27M-Mutant","Embryonal Tumor","Pineal Tumor","Hemangiopericytoma","Hemangioblastoma","Melanocytic Tumor of CNS",[351,352,353,354,355,356,357],"Rare primary brain tumor","2021 WHO Classification","molecular diagnosis","Gliomas","Choroid plexus tumors","Embryonal tumors","Pineal tumors","2025-12-11",{"date":360,"type":40},"2025-12-17",{"date":362,"type":40},"2023-03-21",{"date":364,"type":20},"2038-07-29",{"name":366,"class":190},"European Organisation for Research and Treatment of Cancer - EORTC",42,{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":21,"phases":377,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":87},"100588167","phase-1-maintenance-zanzalintinib-with-etoposide-after-hdct-in-gct-100588167","NCT06937866","Maintenance Zanzalintinib With Etoposide After HDCT in GCT","Maintenance Zanzalintinib With Oral Etoposide Following High-dose Chemotherapy in Patients With Relapsed Metastatic Germ-cell Tumor","Inclusion Criteria:\n\nPhase I:\n\n1. Histological or serological evidence of incurable, refractory or relapsed metastatic germ cell tumor, including seminoma, non-seminoma, and women with ovarian GCTs.\n2. Must have received initial cisplatin-based combination chemotherapy AND demonstrated progression following at least one salvage regimen for advanced germ-cell neoplasm and now considered incurable with standard therapies, including further chemotherapy or surgery.\n\n   2.1. \"Failure\" of prior therapy is defined as: 2.1.1.A \\>25% increase in the products of the perpendicular diameters of measurable tumor masses during prior therapy which are not amenable to surgical resection.\n\n   2.1.2.The presence of new tumors that are not amenable to surgical resection 2.1.3.An increase in AFP or beta-hcg (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of failure).\n\n   NOTE: Patients with clinically growing teratoma (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery.\n3. Subjects with relapsed primary mediastinal non-seminomatous germ-cell tumor (PMNSGCT) or late relapse (\\>2 years) not amenable to resection are eligible if they have received first line platinum-based chemotherapy and are deemed not amenable to surgical resection.\n\nPhase II:\n\n1. Histological or serological evidence of non-seminomatous GCT\n2. Relapsed disease after first-line cisplatin-based combination chemotherapy\n3. Completed salvage treatment with HDCT and PBSCT for 2 tandem cycles per Institutional Guidelines\n4. HDCT must have been used as the initial salvage chemotherapy regimen (2nd line therapy) 4.1. Note: 1 or 2 cycles of standard course regimens prior to HDCT are acceptable (regimens including VeIP \\[vinblastine+ifosfamide+cisplatin\\] or TIP \\[paclitaxel+ifosfamide+cisplatin\\] or PVB \\[cisplatin+vinblastine+bleomycin\\]\n5. Normal or declining tumor markers (AFP and hCG) at time of screening per discretion of treating physician. Patients need to be considered disease free with no known active residual GCT.\n6. Last dose of HDCT must be ≤ 16 weeks from study registration\n7. Women with ovarian germ cell tumors are eligible\n\nFor All Patients:\n\n1. Written informed consent and HIPAA authorization for release of personal health information.\n2. Capable of understanding and complying with the protocol requirements.\n3. Age ≥ 18 years at the time of consent.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 28 days of study registration\n5. Adverse events from prior therapy recovered to CTCAE v5.0 grade ≤ 2 at time of registration unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy (eg, physiological replacement of corticosteroid).\n6. Adequate laboratory values obtained within 14 days prior to registration for protocol therapy and as defined below:\n\n   6.1. Hemoglobin ≥ 9g\u002FdL 6.2. WBC ≥ 2500\u002FµL 6.3. Absolute neutrophil count ≥ 1500\u002Fmm3 6.4. Platelet count ≥ 100,000\u002Fmm3 6.5. Total bilirubin ≤ 1.5 X ULN except patients with documented Gilbert's syndrome (≤ 3 X ULN) 6.6. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤3 X ULN; for patients with hepatic metastases, ALT and AST ≤ 5 X ULN. For subjects with documented bone metastasis ALP ≤ 5 X ULN. 6.7. Serum albumin ≥ 2.8g\u002FdL 6.8. (PT)\u002FINR or partial thromboplastin time (PTT) test ≤ 1.5 x upper limit of normal and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN). 6.9. Calculated creatinine clearance\n\n   ≥ 50 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the Cockcroft Gault equation. 6.10. Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol) creatinine.\n7. Sexually active fertile subjects and their partners must agree to use highly effective method of contraception (defined in Appendix II) during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.\n\n   1. through 186 days after the last dose of zanzalintinib for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib for men,\n   2. through 180 days for women of childbearing potential (WOCBP) or through 120 days after the last dose of etoposide for men\n8. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential, and will need a negative pregnancy test, unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause).\n\nNote: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n\nExclusion Criteria:\n\nPhase I:\n\n1\\. Patients who have not received greater than or equal to 1 salvage treatment regimens or have further potentially curative treatment options.\n\nPhase II:\n\n1. Relapsed pure seminoma\n2. Rising tumor markers (AFP and hCG) at time of screening per discretion of treating physician\n3. Patients who completed 2nd cycle of HDCT (time since last dose of HDCT) \\> 16 weeks ago\n\nFor All Patients:\n\n1. Prior treatment with zanzalintinib\n2. Receipt of any type of cytotoxic, small molecule kinase inhibitor, biologic, investigational, or other systemic anticancer therapy (including investigational) within 2 weeks before first dose of study treatment.\n3. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n4. Prior hypersensitivity to etoposide which did not recover with supportive care\n5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.\n6. Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin inhibitors) and platelet inhibitors (eg, clopidogrel). Note: Subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.\n\n   Allowed anticoagulants are the following:\n   1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   2. Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n7. Prior active malignancy is NOT allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast, or prostate cancer, superficial bladder cancer, Gleason \\\u003C Grade 7 and ≤ T2N0M0 prostate cancers, or other cancer for which the subject has been disease-free for at least three years or at discretion of treating physician.\n8. History of psychiatric illness or social situations that would limit compliance with study requirements.\n9. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   9.1. Unstable or deteriorating cardiovascular disorders: 9.1.1. Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new onset angina, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes), unstable or deteriorating cardiovascular disorders.\n\n   9.1.2. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n\n   9.1.3. Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment.\n\n   9.2. Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment. Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n\n   9.3. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: 9.3.1. Tumors invading the GI-tract from external viscera 9.3.2. Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis 9.3.3. Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before the first dose unless cause of obstruction is definitively managed and subject is asymptomatic 9.3.4. Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n\n   9.3.5. Known gastric or esophageal varices 9.3.6. Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks.\n10. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n11. Symptomatic cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation (asymptomatic or radiated lesions allowed).\n12. Lesions invading or encasing any major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta. Note: Subjects with intravascular tumor extension (eg, tumor thrombus in renal vein or inferior V. cava) may be eligible following Principal Investigator approval.\n13. Other clinically significant disorders that would preclude safe study participation.\n\n    13.1. Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n\n    13.2. Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for subjects meeting all of the following criteria: (1) on stable anti-retroviral therapy; (2) CD4+ T cell count ≥ 200\u002FµL; and (3) an undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: To be eligible, participants taking CYP inhibitors (eg, zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts, and viral load are monitored per standard of care by the local health care provider.\n\n    13.3. Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n\n    13.4. Malabsorption syndrome 13.5. Pharmacologically uncompensated\u002Fsymptomatic hypothyroidism. 13.6. Moderate to severe hepatic impairment (Child-Pugh B or C). 13.7. Requirement for hemodialysis or peritoneal dialysis. 13.8. History of solid organ or allogeneic stem cell transplant.\n14. Major surgery (as defined in Appendix B; eg GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Prior laparascopic surgeries (ie, nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 5 days before first dose of study treatment. Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible. Note: Fresh tumor biopsies should be performed at least 5 days before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n15. Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms per electrocardiogram (ECG) within 14 days of study registration.\n\n    Note: If a single ECG shows a QTcF with an absolute value \\> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n16. Pregnant or lactating females.\n17. Inability to swallow tablets or ingest a suspension either orally or by a nasogastric (NG) or gastrostomy (PEG) tube.\n18. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n19. Prior history of myocarditis.\n20. Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n21. Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study.",{"count":376,"type":20},38,[23,129],"This is an open label, single arm phase I\u002FII trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.",[28],[381,382],"zanzalintinib","maintenance chemotherapy","2025-11-19",{"date":385,"type":40},"2025-11-21",{"date":387,"type":40},"2025-11-12",{"date":389,"type":20},"2031-09",{"name":391,"class":86},"Indiana University",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":87},"100482591","molecular-epidemiology-of-pediatric-germ-cell-tumors-100482591","NCT05564026","Molecular Epidemiology of Pediatric Germ Cell Tumors","Pediatric Germ Cell Tumors: Outcomes, Genomics and Epigenetics","Inclusion Criteria:\n\n* Cases will be eligible for the study if they have a primary diagnosis of GCT including germinoma (ICCC code105 9060-9065), teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071), choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105) in all sites including the brain.\n* The patient must be enrolled on APEC14B1 with consent to future contact or enrolled in AEPI10N1 with consent for future contact (N=827). Patients enrolled in AEPI10N1 were recruited from ACCRN07. All patients must be registered with COG by a North American member institution. Note: (history of) treatment on a COG therapeutic trial is not required.\n* Patients must be diagnosed at \\\u003C 20 years of age at the time of GCT diagnosis. Study participants will be followed over time in the survivorship study so there is no maximum age for participation.\n* Participants must be able to complete study related documents in English or Spanish.\n* All patients and\u002For their parents or legal guardians must provide informed consent. Assent will be obtained for participants between the ages of 8-17 years.\n* All institutional, FDA, and NCI requirements for human studies must be met.\n\nExclusion Criteria:\n\n* Participants from AEPI10N1 who did not consent to future contact. Patients who do not meet the eligibility criteria described above or cannot complete study materials in English or Spanish",{"count":400,"type":20},1151,"A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.",[28,403,404,405,406,407,408,409,410],"Germinoma","Teratoma","Embryonal Carcinoma","Yolk Sac Tumor","Choriocarcinoma","Mixed Germ Cell Tumor","Late Effects","Pediatric Germ Cell Tumor","2025-10-23",{"date":413,"type":40},"2025-10-24",{"date":415,"type":40},"2023-04-12",{"date":187,"type":20},{"name":189,"class":190},{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":16,"minAge":425,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":87},"100607429","phase-2-treatment-of-newly-diagnosed-central-malignant-germ-cell-tumor-people-with-teniposide-injection-combined-with-cisplatin-100607429","NCT07188441","Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.","A Single-center, Single-arm, Open-label Study of the Combination of Teniposide Injection and Cisplatin in the Treatment of Newly Diagnosed Patients With Central Malignant Germ Cell Tumors.","Inclusion Criteria:\n\n* Must have at least one measurable lesion defined by RANO criteria\n* The initial diagnosis has been confirmed as central malignant germ cell tumor\n* Expected survival period ≥ 6 months\n* Absolute neutrophil ≥1.0×10\\^9\u002FL; Platelet ≥100.0×10\\^9\u002FL\n* Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal\n* total bilirubin ≤1.5×Upper limit of normal\n* Electronic Case Report of Form≥70mL\u002Fmin\u002F1.73m\\^2\n* Estimated glomerular filtration rate ≥ 70 mL\u002Fmin\u002F1.73 m² or normal serum creatinine (Cr)\n* Women and men with fertility must agree to use appropriate contraceptive methods (hormones or barrier therapy or abstinence) during the study period and within 3 months after the last dose; The pregnancy test of female subjects of childbearing age within 7 days before administration must be negative\n* Willing and able to read, understand, and sign written informed consent, parents\u002Fguardians of child or adolescent subjects have the ability to understand, agree, and sign research informed consent forms and applicable child consent forms before initiating any protocol related procedures\n\nExclusion Criteria:\n\n* Patients undergoing any other anti-cancer experimental treatment\n* Individuals with a history of severe allergies or allergies to any component of the drugs in the past\n* Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia\n* Patients with Magnetic Resonance Imaging contraindications\n* Those who need to receive live virus vaccine during administration\n* Serious complications and\u002For underlying diseases\n* Individuals with poor control of hypertension (under standardized blood pressure reduction protocols, systolic blood pressure ≥ 160mmHg and\u002For diastolic blood pressure ≥ 100mmHg)\n* Uncontrolled systemic bacterial, viral, or fungal infections\n* Patients infected with Human Immunodeficiency Virus(HIV) or syphilis\n* Patients who have undergone organ transplantation in the past\n* Pregnant or lactating women\n* Researchers believe that there are other factors that are not suitable for participating in the experiment","5 Years",{"count":427,"type":20},40,[129],"This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitoring on subjects to explore potential biomarkers for predicting therapeutic efficacy. It is expected to ultimately achieve the goal of prolonging the overall survival of patients, while providing more guidance for the screening of the best treatment population and biological predictive markers.",[431,28,432],"GCT","Central Malignant Germ Cell Tumor",[434,431,435,436],"Central malignant germ cell tumor","teniposide","Cisplatin","2025-09-22",{"date":439,"type":40},"2025-09-23",{"date":441,"type":40},"2024-08-13",{"date":443,"type":20},"2026-12",{"name":445,"class":86},"Chengcheng Guo",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":454,"minAge":56,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":21,"phases":458,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":87},"100526346","robot-assisted-icg-guided-sentinel-node-biopsy-in-testicular-cancer-100526346","NCT06133543","Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer","RAISN - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer","RAISN","Inclusion Criteria:\n\n* Clinically confirmed unequivocal testicular tumor by palpation and sonography with or without elevation of specific tumor markers AFP and\u002For ß-HCG.\n* Clinical exclusion of metastases in preoperative staging using contrast-enhanced CT of the thorax and abdomen.\n* The patient is of legal age.\n* The patient can communicate with the investigator without issues or limitations and can understand and sign the patient information and consent form without problems or limitations.\n\nExclusion Criteria:\n\n* Testicular tumor with uncertain dignity\n* Patients with small testicular masses (\\\u003C 1 cm)\n* Patients with prior scrotal or retroperitoneal surgery for reasons other than a germ cell tumor.\n* The patient has received different chemotherapy.\n* The patient has undergone retroperitoneal radiotherapy.\n* Exclusion criteria for the use of ICG include a history of anaphylactic reactions to ICG and iodine intolerance (ICG solution contains sodium iodide).\n* The patient is in a reduced general condition or has a life-threatening illness.\n* The patient has a psychiatric illness.","MALE","99 Years",{"count":457,"type":20},44,[459],"NA","Robot-assisted image-guided sentinel lymph node biopsy (RAISN) in testicular cancer is a novel technique that has not been widely investigated yet. This technique is promising and could be implemented as a future standard in the primary diagnostic work up of clinical stage (CS) I testicular cancer. Current staging strategies have a poor predictive accuracy for occult metastatic disease.\n\nSo far, feasibility studies used 99mTC-nanocolloid staining and laparoscopy and all patients with tumor-positive nodes received adjuvant systemic treatment. The development of a robot-assisted image-guided lymph node resection technique with indocyanine green (ICG) is potentially more precise, easier to apply and widely available. With this new diagnostic approach the management of newly diagnosed testicular cancer patients might be changed dramatically by reducing overtreatment and treatment-related toxicity with a minimally invasive robot-assisted procedure.",[28,462,463],"Seminoma","Nonseminomatous Germ Cell Tumor","2025-09-09",{"date":466,"type":40},"2025-09-15",{"date":468,"type":40},"2023-09-06",{"date":470,"type":20},"2028-03-31",{"name":472,"class":86},"Heinrich-Heine University, Duesseldorf",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":454,"minAge":56,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":21,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":87},"100548268","phase-2-high-dose-chemotherapy-as-second-line-drug-therapy-for-relapsed-germ-cell-tumors-100548268","NCT06418789","High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors","GERMAN","Inclusion Criteria:\n\n1. Patient is able to provide informed consent and sign approved consent forms to participate in the study.\n2. Males ≥ 18 years of age at the time of signing the IC Form.\n3. Histologically verified diagnosis of GO (seminomatous, non-seminomatous).\n\n2\\. Any (gonadal and extragonadal (retroperitoneal, mediastinal, etc.)) localization of primary GO.\n\n3\\. Progression after 3 or 4 cycles of platinum-containing first-line chemotherapy (ВЕР or EP).\n\n4\\. Required Initial Laboratory Values:\n\n* Hemoglobin ≥ 90 g\u002FL;\n* neutrophils ≥ 1.5 x 109\u002FL;\n* platelets ≥ 75 x 109\u002FL;\n* creatinine ≥ 1.5 x HGH (or CKF ≤ 60 mL\u002Fmin);\n* ALT or AST ≥ 2.5 x HGN (5 x HGN for patients with liver metastases);\n* bilirubin ≥ 1.5 x IUH (except for patients with Gilbert syndrome, in whom total bilirubin levels should not exceed 50 μmol\u002FL);\n* alkaline phosphatase ≥ 2.5 x IUH. 5. Absence of neurologic symptoms in the presence of CNS metastases (asymptomatic CNS metastases are acceptable).\n\nExclusion Criteria:\n\n1. Primary CS of the brain\n2. Administration of ≥2 lines of prior drug therapy for disseminated GO.\n3. Presence of active hepatitis B or hepatitis C, HIV infection, acute infectious disease, or activation of chronic infectious disease less than 28 days prior to study inclusion.\n4. Conditions that limit the patient's ability to fulfill the requirements of the protocol (psychiatric disorders, drug or alcohol dependence).",{"count":58,"type":20},[129],"This is a prospective, single-center, non-randomized phase II study. Patients with germ cell tumors of gonadal and extragonadal localization who have progressed after prior platinum-containing first-line chemotherapy will receive high-dose chemotherapy with TI (2 cycles) folollowed by high dose CE chemotherapy with autologous stem cell transplantation (3 cycles). The primary endpoint of the study is to evaluate the efficacy high-dose chemotherapy as second-line drug therapy for patients with advanced germ cell tumors.",[28],[28,404,407,403,485,486,462,132,406,408,487],"Childhood Teratoma","Extragonadal Seminoma","Malignant Germ Cell Neoplasm","2025-07-30",{"date":490,"type":40},"2025-08-03",{"date":492,"type":40},"2024-03-01",{"date":494,"type":20},"2029-03-01",{"name":496,"class":86},"N.N. Petrov National Medical Research Center of Oncology",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":454,"minAge":56,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":21,"phases":506,"briefSummary":507,"conditions":508,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":518},"100506413","phase-3-thromboprophylaxis-in-good-and-intermediate-prognosis-advanced-germ-cell-tumors-100506413","NCT05874063","Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors","GIG-T","Inclusion Criteria:\n\n* Diagnosis of good or intermediate prognosis of Germ Cell Tumor (according to the International Germ Cell Cancer Collaborative Group)\n* Older than 18 years\n* Suitable for first-line cisplatin-based chemotherapy\n* No prior systemic cytotoxic therapy\n* Additional criteria for patients who will be randomized (Venous Thromboembolic Event (VTE) high-risk patients): Lactate dehydrogenase higher than 1 Upper Normal Level and\u002For Body Surface Area higher than 1.9 and\u002For longer than 5 cm long axis retroperitoneal lymph nodes\n* Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.\n* Patients must be affiliated to a social security system or beneficiary of the same\n\nExclusion Criteria:\n\n* Brain metastasis\n* History of VTE\n* Concomitant use of anticoagulants or antiaggregants\n* Renal impairment defined as creatinine clearance less than 50 ml\u002Fmin using Cockcroft-Gault formula\n* Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients\n* Any major surgery (i.e. open surgery lasting more than 45 minutes from opening to closure) within 4 weeks or planned during the study treatment period\n* Severe uncontrolled high blood pressure (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg)\n* Low baseline platelet count (\\\u003C 100 X 10\\^9 \u002FL) or history of heparin-induced thrombocytopenia\n* Active clinically significant bleeding and conditions with a high risk of haemorrhage, including recent haemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities\n* Extensive metastatic disease at high risk of bleeding, e.g. prevalent choriocarcinoma\n* Participation in another clinical study with an investigational product during the last 4 weeks, and while on study treatment without the approval from sponsor\n* Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent",{"count":505,"type":20},387,[151],"The goal of this clinical trial is to assess the efficacy of thromboprophylaxis in preventing venous thromboembolic events (VTE) in good and intermediate prognosis patients with metastatic germ cell cancer (GCT) undergoing first-line cisplatin-based chemotherapy with risk factors for developing a thromboembolic event .\n\nThe high-risk patients will be randomized between two treatments arm (receiving a thromboprophylaxis in the experimental arm, or no thromboprophylaxis in the control arm). The low-risk patients will be observed without any thromboprophylaxis. Patients will participate in the study for 14-17 weeks depending on the planned number of cycles of chemotherapy.\n\nResearchers will compare an experimental arm with thromboprophylaxis and a control arm without thromboprophylaxis to detect an absolute decrease of 12% of the proportion of patients having experienced a VTE, from 21% (high risk patients, control arm) to 9% (high risk patients, experimental arm).",[28],"2025-06-13",{"date":511,"type":40},"2025-06-15",{"date":513,"type":40},"2023-10-17",{"date":515,"type":20},"2028-02",{"name":517,"class":86},"Gustave Roussy, Cancer Campus, Grand Paris",26,{"id":520,"slug":521,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":16,"minAge":527,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":21,"phases":531,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":545},"100253804","phase-3-accelerated-vs-standard-bep-chemotherapy-for-patients-with-intermediate-and-poor-risk-metastatic-germ-cell-tumours-100253804","NCT02582697","Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","P3BEP","Inclusion Criteria:\n\n1. Age ≥ 11 years and ≤ 50 years on the date of randomisation\n2. Histologically or cytologically confirmed germ cell tumour (non-seminoma or seminoma); or Exceptionally raised tumour markers (AFP ≥ 1000ng\u002FmL and\u002For HCG ≥ 5000 IU\u002FL) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently\n3. Primary arising in testis, ovary, retro-peritoneum, or mediastinum\n4. Metastatic disease or non-testicular primary\n5. Intermediate or poor prognosis as defined by IGCCC classification3 (modified with different LDH criteria for intermediate risk non-seminoma, and inclusion of ovarian primaries). (See protocol for more information).\n6. Adequate bone marrow function with ANC ≥1.0 x 10\\^9\u002FL, Platelet count ≥100 x 10\\^9\u002FL\n7. Adequate liver function where bilirubin must be ≤1.5 x ULN, except participants with Gilbert's Syndrome where bilirubin must be ≤2.0 x ULN; ALT and AST must be ≤2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be ≤ 5 x ULN\n8. Adequate renal function with estimated creatinine clearance of ≥60 ml\u002Fmin according to the Cockcroft-Gault formula, unless calculated to be \\\u003C 60 ml\u002Fmin or borderline in which case GFR should be formally measured, eg. with EDTA scan\n9. ECOG Performance Status of 0, 1, 2, or 3\n10. Study treatment both planned and able to start within 14 days of randomisation.\n11. Willing and able to comply with all study requirements, including treatment, timing and nature of required assessments\n12. Able to provide signed, written informed consent\n\nExclusion Criteria:\n\n1. Other primary malignancy (EXCEPT adequately treated non-melanomatous carcinoma of the skin, germ cell tumour, or other malignancy treated at least 5 years previously with no evidence of recurrence)\n2. Previous chemotherapy or radiotherapy, except if patient has pure seminoma relapsing after adjuvant radiotherapy or adjuvant chemotherapy with 1-2 doses of single agent carboplatin or if patient hasb. non-seminoma by IGCCC criteria or stage IV malignant ovarian germ cell tumour in the rare case where low-dose induction chemotherapy is given prior to registration because patient is not fit enough to receive protocol chemotherapy (eg. organ failure, vena cava obstruction, overwhelming burden of disease). Acceptable regimens include cisplatin 20 mg\u002Fm2 days 1-2 and etoposide 100 mg\u002Fm2 days 1-2; carboplatin AUC 3 days 1-2 and etoposide 100 mg\u002Fm2 days 1-2; or baby-BOP.43 Patients must meet all other inclusion and exclusion criteria at the time of registration.\n\n   Additionally participants who need to start therapy urgently prior to completing study-specific baseline investigations may commence study chemotherapy prior to registration and randomisation. Such patients must be discussed with the coordinating centre prior to registration, and must be registered within 10 days of commencing study chemotherapy.\n3. Significant cardiac disease resulting in inability to tolerate IV fluid hydration for cisplatin\n4. Significant co-morbid respiratory disease that contraindicates the use of bleomycin\n5. Peripheral neuropathy ≥ grade 2 or clinically significant sensorineural hearing loss or tinnitus\n6. Concurrent illness, including severe infection that may jeopardize the ability of the participant to undergo the procedures outlined in this protocol with reasonable safety\n7. Inadequate contraception. Men must use 2 effective methods of contraception, including use of a condom, during chemotherapy and for a year after completing chemotherapy.\n8. Known allergy or hypersensitivity to any of the study drugs\n9. Presence of any psychological, familial, sociological or geographical condition that in the opinion of the investigator would hamper compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse\n\nThe above inclusion and exclusion criteria will apply to stage 1 (n=150) and stage 2 (n=500 including stage 1) of the study. All sites will participate in both stages of the study with the exception of the Children's Oncology Group who will be participate in stage 1 only.","11 Years","50 Years",{"count":530,"type":20},500,[151],"The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.",[28],[535,536],"Germ Cell","Intermediate and poor-risk metastatic germ cell tumours","2025-06-11",{"date":511,"type":40},{"date":540,"type":40},"2014-02",{"date":542,"type":20},"2029-12-31",{"name":544,"class":86},"University of Sydney",28,{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":454,"minAge":56,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":21,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":87},"100507607","morbidity-long-term-side-effects-and-quality-of-life-in-germ-cell-tumor-long-survivors-treated-with-high-dose-chemotherapy-and-autologous-stem-cell-transplant-100507607","NCT05889585","Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant","HGT-QoL","Inclusion Criteria:\n\n* Age ≥ 18 years at diagnosis\n* Treated between 1990 and 2015\n* Histologically confirmed diagnosis of germ cell tumor (or high level serum tumor marker-based) and:\n\nTreated for relapse with high-dose of chemotherapy (HDCT) with autologous transplant at Gustave Roussy and relapse-free.\n\nOr Treated by orchiectomy only and no evidence of relapse after a minimum of 3 years.\n\nOr Good or intermediate prognosis metastatic disease according to the IGCCCG, treated by first line cisplatin-based chemotherapy at Gustave Roussy (and surgery of residual masses if needed), with no evidence of relapse.\n\n* Ability to comply with the protocol procedures\n* Patient affiliated to a social security system or beneficiary of the same. 6-Who have signed a written informed consent form prior to any study specific procedure.\n\nExclusion Criteria:\n\n* Diagnosis of second malignancy\n* Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and\u002For his compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.\n* Patient under guardianship or deprived of his\u002Fher liberty by a judicial or administrative decision, or incapable of giving his\u002Fher consent.",{"count":554,"type":20},180,[459],"Intensified chemotherapy is an effective treatment in 30-70% of patients with refractory germ cell tumor. Since most cases are diagnosed before the age of 40, survivors can expect to live another 30 to 50 years after being successfully treated. Long-term side effects and physical and emotional consequences can therefore have a significant impact on daily life. To date, no data of this type is available in France. This study will help clinicians better understand the long-term consequences for relapsed patients receiving high-dose chemotherapy.",[28],"2024-10-16",{"date":560,"type":40},"2024-10-18",{"date":562,"type":40},"2023-05-31",{"date":564,"type":20},"2025-05",{"name":517,"class":86},{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":574,"targetDuration":576,"studyType":204,"phases":4,"briefSummary":577,"conditions":578,"keywords":583,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":87},"100548500","establishing-prospective-mediastinal-tumor-database-of-pumch-100548500","NCT06421805","Establishing Prospective Mediastinal Tumor Database of PUMCH","A Single-center, Prospective, and Observational Study on Population Characteristics, Pathological Features, and Prognostic Factors of Patients With Mediastinal Tumor: Establishing Mediastinal Tumor Database of PUMCH.","MTDPUMCH","Inclusion Criteria:\n\n1. Clinical or pathological diagnosis of mediastinal tumors;\n2. Written consent is able to obtained.\n\nExclusion Criteria:\n\n1\\. Incomplete clinicopathological information.",{"count":575,"type":20},2000,"20 Years","This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors. Clinical information will be structured and processed, and it is recommended to establish a mediastinal tumors database at Peking Union Medical College Hospital. The goal is to provide support for the quality of diagnosis and treatment, clinical protocols, and medical decision-making related to mediastinal tumors.",[579,404,580,581,28,74,582],"Thymic Epithelial Tumor","Thymic Cyst","Retrosternal Goitre","Schwannoma",[584,585,586],"mediastinal tumors","database","thymic epithelial tumor","2024-05-14",{"date":589,"type":40},"2024-05-20",{"date":591,"type":40},"2012-01-01",{"date":593,"type":20},"2045-12-30",{"name":595,"class":86},"Peking Union Medical College Hospital",{"id":597,"slug":598,"hasResults":11,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":603,"minAge":604,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":607,"conditions":608,"keywords":615,"overallStatus":618,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":4},"100541396","serum-and-plasma-micrornas-in-malignant-ovarian-germ-cell-tumours-100541396","NCT06329323","SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours","SUMMER","Inclusion Criteria:\n\n* All patients with a new diagnosis of a malignant ovarian germ cell tumour.\n* The control population will include all patients with a new diagnosis of a benign ovarian germ cell tumour or no known gynaecological pathology.\n\nExclusion Criteria:\n\n* Previous or ongoing chemotherapy for MOGCT\n* Previous surgery for MOGCT\n* Pregnancy - this will be verbally communicated for those not having surgery or chemotherapy, for those having surgery or chemotherapy a urine pregnancy test should be negative and documented in the clinical notes.\n* Fetal circulating DNA is known to be present in maternal blood and therefore pregnant women should not be included in this study\n* Denial of informed consent\n* Age \\\u003C16 years\n* History of any other cancer","FEMALE","16 Years",{"count":606,"type":20},24,"The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign OGCT and no ovarian pathology.\n\nThe main question\\[s\\] it aims to answer are:\n\n1. To understand the circulating miRNA expression of malignant ovarian germ cell tumours (MOGCTs) compared to those with benign ovarian germ cell tumours (BOGCTs)\n2. To understand the imaging profile of MOGCTs compared to that of BOGCTs\n3. To establish the relationship between serum and plasma miRNA expression in response to treatment and relapse of disease\n4. To discover if miRNA expression correlates with radiomic features of OGCTs on both ultrasound and MRI\n5. To see if we can link the micro RNAs in tumour samples to those found in blood samples, and to find a plausible explanation for why these micro RNAs are raised (in terms of the tumour biology itself).aims\n\nParticipants will have serial blood tests at different time points in their care to assess how circulating miRNA levels are affected by treatment and\u002For remission and\u002For relapse. If they have surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their mass.\n\nResearchers will compare the circulating miRNA profile of patients with a benign ovarian germ cell tumour and no ovarian pathology to see where the differences lie. If a patient with a BOGCT requires surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their benign mass.",[609,28,610,611,612,613,26,614],"Germ Cell Ovarian Cancer","Germ Cell Cancer","Germ Cell Neoplasia","Ovary Cancer","Ovary Neoplasm","Ovarian Neoplasms",[610,616,617,26],"microRNA","miRNA","NOT_YET_RECRUITING","2024-03-25",{"date":621,"type":40},"2024-03-26",{"date":623,"type":20},"2024-04-14",{"date":625,"type":20},"2028-04",{"name":627,"class":86},"Imperial College London",{"id":629,"slug":630,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":11,"sex":16,"minAge":636,"maxAge":56,"enrollmentInfo":637,"targetDuration":425,"studyType":204,"phases":4,"briefSummary":639,"conditions":640,"keywords":644,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":87},"100490893","genetic-and-molecular-risk-profiles-of-pediatric-malignant-brain-tumors-in-china-100490893","NCT05672043","Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China","Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China","GRIPP","Inclusion Criteria:\n\n\\- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid\u002Frhabdoid tumors, ependymoblastoma, and medulloepithelioma;\n\nPatients must be eligible for and receive tumor resection;\n\nHistological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;\n\nParticipants consent with joining the current study and comply with follow-up visits;\n\nThe patients must have no previous radiotherapy or chemotherapy other than corticosteroids.\n\nExclusion Criteria:\n\n\\- Patients with major perioperative complications which lead to significant and sudden deterioration;\n\nPatients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis;\n\nPatients with major adverse events or sudden deterioration irrelevant to the current study;\n\nQuality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations;\n\nPatients who refuse to participate in the study or who request dropping out from the study","0 Years",{"count":638,"type":20},400,"Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.",[641,642,263,28,76,643],"Medulloblastoma","Central Nervous System Tumor, Pediatric","Brain Tumor, Pediatric",[645,646],"medulloblastoma","pediatric brain tumor","2023-01-03",{"date":649,"type":40},"2023-01-05",{"date":651,"type":40},"2023-01-01",{"date":653,"type":20},"2032-12-31",{"name":655,"class":86},"Beijing Tiantan Hospital",{"id":657,"slug":658,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":21,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":87},"100477842","multidisciplinary-approach-to-fatigue-100477842","NCT05502224","Multidisciplinary Approach to Fatigue","Pilot Project for the Implementation of an Integrated Multidisciplinary Follow-up for Young Patients With Breast Cancer or Germ Cell Tumor","Inclusion Criteria:\n\n* Age between 18 and 39 years at the time of signing the informed consent\n* Patient who speaks and understands French\n* Signed study informed consent form obtained prior to any study related procedures\n* At minimum, a moderate (\\>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program\n* Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patient having chosen to participate in another psychosocial intervention study for the duration of the study.\n* Patients with AJCC stage IV breast cancer","39 Years",{"count":665,"type":20},50,[459],"Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour",[669,28],"Breast Cancer","2022-11-07",{"date":672,"type":40},"2022-11-08",{"date":674,"type":40},"2022-08-19",{"date":676,"type":20},"2027-09",{"name":678,"class":86},"Jules Bordet Institute"]